You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pulmonary arterial hypertension (PAH)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With

Not yet recruiting
  • Pulmonary Arterial Hypertension
  • +3 more
  • 129Xe Hyperpolarized
  • Durham, North Carolina
    Duke University Medical Center
Oct 23, 2023

Pulmonary Arterial Hypertension Trial (Sotatercept)

Not yet recruiting
  • Pulmonary Arterial Hypertension
  • Sotatercept
  • (no location specified)
Apr 5, 2023

d Plasma Volume in Pulmonary Hypertension

Completed
  • Pulmonary Arterial Hypertension
  • +2 more
    • (no location specified)
    May 5, 2023

    Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

    Not yet recruiting
    • Idiopathic Pulmonary Arterial Hypertension
    • +2 more
    • No Intervention
    • (no location specified)
    Jul 14, 2022

    Prospective, Non-interventional, Multi-center,

    Recruiting
    • Hypertension, Pulmonary
    • Riociguat (ADEMPAS, BAY63-2521)
    • Multiple Locations, Japan
      Many Locations
    Aug 17, 2022

    Pulmonary Arterial Hypertension Trial in Kansas City (Placebo, Seralutinib, Generic Dry Powder Inhaler)

    Not yet recruiting
    • Pulmonary Arterial Hypertension
    • Placebo
    • +2 more
    • Kansas City, Kansas
      University of Kansas Medical Center
    Jun 28, 2023

    Pulmonary Arterial Hypertension Trial in Shanghai (TPN171H)

    Completed
    • Pulmonary Arterial Hypertension
    • Shanghai, China
      Fu Zhu
    Jul 6, 2023

    Pulmonary Arterial Hypertension (PAH) Trial in China (as per Physician's prescription)

    Active, not recruiting
    • Pulmonary Arterial Hypertension (PAH)
    • as per Physician's prescription
    • Beijing, Beijing, China
    • +6 more
    Sep 14, 2022

    Pulmonary Arterial Hypertension Trial in Cincinnati (Sotatercept)

    Recruiting
    • Pulmonary Arterial Hypertension
    • Cincinnati, Ohio
      Cincinnati Children's Hospital Medical Center ( Site 1602)
    Jan 31, 2023

    Pulmonary Arterial Hypertension (PAH) Trial in Lahore (aerobic exercises, active alternating movements for the upper limbs)

    Not yet recruiting
    • Pulmonary Arterial Hypertension (PAH)
    • aerobic exercises
    • active alternating movements for the upper limbs
    • Lahore, Punjab, Pakistan
      National hospital and Ittefaq hospital in Lahore
    Jul 7, 2023

    Pulmonary Arterial Hypertension Trial (Selexipag, Riociguat, CardioMEMS pulmonary artery pressure monitor)

    Not yet recruiting
    • Pulmonary Arterial Hypertension
    • (no location specified)
    Apr 11, 2023

    Pulmonary Arterial Hypertension Trial in Sydney (Dose A KER-012, Dose B KER-012, Dose C KER-012)

    Recruiting
    • Pulmonary Arterial Hypertension
    • Dose A KER-012
    • +3 more
    • Sydney, Australia
      Macquarie University
    Jul 27, 2023

    Pulmonary Arterial Hypertension PAH Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (ZMA001 (BC-NKA-20008),

    Not yet recruiting
    • Pulmonary Arterial Hypertension PAH
    • ZMA001 (BC-NKA-20008)
    • Placebo
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 3, 2023

    Pulmonary Arterial Hypertension Trial (Treprostinil Palmitil, Placebo)

    Not yet recruiting
    • Pulmonary Arterial Hypertension
    • Treprostinil Palmitil
    • Placebo
    • (no location specified)
    Dec 6, 2022

    StratosPHere (Non-interventional Study)

    Completed
    • Pulmonary Arterial Hypertension
    • +3 more
      • Cambridge, England, United Kingdom
        University of Cambridge Heart and Lung Research Institute
      Mar 2, 2023

      Pulmonary Arterial Hypertension Trial in Indianapolis (AV-101)

      Recruiting
      • Pulmonary Arterial Hypertension
      • Indianapolis, Indiana
        Indiana University Health
      Dec 6, 2022

      Pulmonary Artery Hypertension Trial (XBD173)

      Not yet recruiting
      • Pulmonary Artery Hypertension
      • (no location specified)
      Sep 6, 2023

      Hypertension, Pulmonary Trial in Worldwide (Riociguat (Adempas, BAY63-2521))

      Active, not recruiting
      Has Results
      • Hypertension, Pulmonary
      • Riociguat (Adempas, BAY63-2521)
      • Cali, Valle Del Cauca, Colombia
      • +15 more
      Jan 18, 2023

      Pulmonary Arterial Hypertension Trial in United States (Treprostinil Palmitil)

      Recruiting
      • Pulmonary Arterial Hypertension
      • Treprostinil Palmitil
      • Tucson, Arizona
      • +3 more
      Jul 11, 2022

      Pulmonary Arterial Hypertension Trial in Worldwide (Oral zamicastat)

      Completed
      • Pulmonary Arterial Hypertension
      • Oral zamicastat
      • Linz, Austria
      • +10 more
      Aug 18, 2023

      Hypertension, Pulmonary Trial in Worldwide (Adempas (Riociguat, BAY63-2521))

      Recruiting
      • Hypertension, Pulmonary
      • Adempas (Riociguat, BAY63-2521)
      • Besancon, France
      • +15 more
      Jan 31, 2023

      Pulmonary Hypertension Trial in United States (ABI-009, nab-rapamycin, albumin-bound rapamycin)

      Active, not recruiting
      • Pulmonary Hypertension
      • ABI-009, nab-rapamycin, albumin-bound rapamycin
      • Tucson, Arizona
      • +5 more
      Aug 22, 2022

      Lung in Pulmonary Artery Hypertension (PAH)

      Not yet recruiting
      • Pulmonary Arterial Hypertension
      • Healthy
      • TSPO PET scan (11C-PBR28)
      • (no location specified)
      Feb 16, 2023

      Systemic Sclerosis, Pulmonary; Hypertension Trial in United States (Dimethyl Fumarate (DMF), Placebo Oral Tablet)

      Terminated
      Has Results
      • Systemic Sclerosis
      • Pulmonary; Hypertension
      • Dimethyl Fumarate (DMF)
      • Placebo Oral Tablet
      • Denver, Colorado
      • +3 more
      Mar 15, 2022

      Pulmonary Arterial Hypertension (PAH) Trial in Los Angeles (Allogeneic Human Cardiosphere-Derived Stem Cells, Placebo)

      Active, not recruiting
      • Pulmonary Arterial Hypertension (PAH)
      • Allogeneic Human Cardiosphere-Derived Stem Cells
      • Placebo
      • Los Angeles, California
        Cedars-Sinai Medical Center
      Mar 7, 2022